

#4264 Store at -20C

FXR1 (L662) Antibody



Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: WB	Reactivity: M	Sensitivity: Endogenous	MW (kDa): 78-80, 82-84	Source: Rabbit	UniProt ID: #P51114	Entrez-Gene Id: 8087
----------------------------	-------------------------	-----------------------------------	----------------------------------	--------------------------	-------------------------------	--------------------------------

Product Usage Information	Application Western Blotting	Dilution 1:1000
Storage	Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.	
Specificity / Sensitivity	FXR1 (L662) Antibody detects endogenous levels of total FXR1 protein.	
Source / Purification	Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the sequence of mouse FXR1 protein. Antibodies are purified by protein A and peptide affinity chromatography.	
Background	Fragile X syndrome is a genetic disorder characterized by a spectrum of physical and behavioral features and is a frequent form of inherited mental retardation (1). X-linked FMRP (FMR-1) and its two autosomal homologs, FXR1 and FXR2, are polyribosome-associated RNA-binding proteins that are involved in the pathogenesis of fragile X syndrome (1-3). Each of the fragile X proteins can self-associate, as well as form heteromers with the other two related proteins (3). FMRP can act as a translation regulator and is a component of RNAi effector complexes (RISC), suggesting a role in gene silencing (4). The <i>Drosophila</i> homolog of FMRP (dFMRP) associates with Argonaute 2 (Ago2) and Dicer and can coimmunoprecipitate with miRNA and siRNA (5). These results suggest that fragile X syndrome is related to abnormal translation caused by defects in RNAi-related pathways. In addition, FMRP, FXR1, and FXR2 are components of stress granules (SG) and have been implicated in the translational regulation of mRNAs (6).	
Background References	<ol style="list-style-type: none"> 1. Verkerk, A.J. et al. (1991) <i>Cell</i> 65, 905-14. 2. Siomi, M.C. et al. (1995) <i>EMBO J</i> 14, 2401-8. 3. Zhang, Y. et al. (1995) <i>EMBO J</i> 14, 5358-66. 4. Caudy, A.A. et al. (2002) <i>Genes Dev</i> 16, 2491-6. 5. Siomi, H. et al. (2004) <i>Ment Retard Dev Disabil Res Rev</i> 10, 68-74. 6. Linder, B. et al. (2008) <i>Hum Mol Genet</i> 17, 3236-46. 	

Species Reactivity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key	WB: Western Blotting
Cross-Reactivity Key	H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.